Work

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-159409

Authors: Joseph Scandura, Srdan Verstovsek, Marina Kremyanskaya, Moshe Talpaz, Raajit K Rampal, Alessandro Vannucchi, Vikas Gupta, Francesca Palandri, Andrea Patriarca, Prithviraj Bose, Dong Chen, Oksana Zavidij, Jike Cui, Tzuu-Wang Chang, Pietro Taverna, John Mascarenhas, Claire Harrison

Institutions: Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Michigan, U-M Rogel Cancer Center, Memorial Sloan Kettering Cancer Center, Azienda Ospedaliero-Universitaria Careggi, University of Toronto, Istituto di Ematologia di Bologna, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Azienda Ospedaliero Universitaria Maggiore della Carita, Mayo Clinic, Constellation Pharmaceuticals (United States), Guy's and St Thomas' NHS Foundation Trust

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310107748

FWCI: 0.254

Cites:

Cited by: 2

Related to: 10